The LIPFENDRA FDA approval marks the arrival of the first and only once-daily oral PCSK9 inhibitor cleared by the U.S. Food and Drug Administration to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. Announced July 16, 2026 from Rahway, New Jersey, the approval covers LIPFENDRA (enlicitide) tablets 20 mg as an adjunct to diet and exercise, including in patients with heterozygous familial hypercholesterolemia (HeFH).
Merck (NYSE: MRK), known as MSD outside the United States and Canada, says the clearance is significant because it brings PCSK9 inhibition, previously available only through injectable biologics, into pill form. LIPFENDRA is built on a novel macrocyclic peptide platform that binds PCSK9 and blocks its interaction with LDL receptors, allowing the liver to clear more LDL-C, often called “bad cholesterol,” from the bloodstream.
CORALreef Phase 3 Trials Behind the LIPFENDRA FDA Approval
In CORALreef Lipids, LIPFENDRA lowered LDL-C by a placebo-adjusted 56% at week 24 (95% CI: -61, -51; p<0.001), reflecting a 57% drop from baseline versus a 3% increase for placebo. Under revised, post-hoc data-handling rules that excluded biologically impossible LDL-C values at or below zero, the reduction reached 60% versus placebo. In CORALreef HeFH, LIPFENDRA cut LDL-C by 59% compared to placebo (95% CI: -66, -53; p<0.001) a 58% reduction from baseline against a 3% rise for placebo.
Secondary Endpoints: Non-HDL-C and ApoB Reductions with LIPFENDRA
Beyond LDL-C, LIPFENDRA produced statistically significant reductions in other atherogenic lipoproteins tied to atherosclerotic cardiovascular disease (ASCVD) risk. In CORALreef Lipids, non-HDL-C fell by a mean of 54% and ApoB by 50%, versus a 3% placebo increase. In CORALreef HeFH, non-HDL-C dropped 52% and ApoB 48%, against a 2% placebo increase.
CORALreef Phase 3 Efficacy Data (Week 24)
| Endpoint | CORALreef Lipids (LIPFENDRA vs. Placebo) | CORALreef HeFH (LIPFENDRA vs. Placebo) |
|---|---|---|
| LDL-C reduction vs. placebo | 56% (95% CI: -61, -51; p<0.001) | 59% (95% CI: -66, -53; p<0.001) |
| LDL-C change from baseline | -57% vs. +3% | -58% vs. +3% |
| LDL-C reduction (post-hoc, excluding ≤0 values) | 60% vs. +3% | Not reported |
| Non-HDL-C reduction from baseline | 54% vs. +3% | 52% vs. +2% |
| ApoB reduction from baseline | 50% vs. +3% | 48% vs. +2% |
Safety Profile Reviewed in the LIPFENDRA FDA Approval
In CORALreef Lipids, adverse reaction rates were similar between LIPFENDRA and placebo groups, and comparable proportions of patients in each arm discontinued treatment due to an adverse reaction. In CORALreef HeFH, the most common adverse reactions occurring at higher rates than placebo were diarrhea and dizziness. Discontinuation rates due to adverse events were again similar between arms, and Merck said the overall safety profile in HeFH patients was consistent with the broader CORALreef Lipids population.
CORALreef Safety Data (Adverse Reactions, HeFH Trial)
| Adverse Reaction | LIPFENDRA | Placebo |
|---|---|---|
| Diarrhea | 7% | 2% |
| Dizziness | 9% | 4% |
Expert Voices: Cardiology and Patient Advocacy Perspectives
Dr. Ann Marie Navar, a lead author of the CORALreef Lipids study and associate professor of medicine in the Division of Cardiology at UT Southwestern Medical Center, said high LDL-C remains a major driver of atherosclerotic cardiovascular disease, calling it the leading cause of death globally. She noted that LIPFENDRA produced impressive LDL-C reductions across two Phase 3 trials and gives patients an oral PCSK9 inhibitor for the first time.
Katherine Wilemon, CEO of the Family Heart Foundation, added that timely identification and treatment of risk factors such as LDL-C is one of the greatest opportunities to manage ASCVD risk, and welcomed LIPFENDRA as a new oral option for adults who need additional LDL-C lowering.
Merck also disclosed that an ongoing outcomes trial is studying whether LIPFENDRA reduces cardiovascular morbidity and mortality, that data is not yet available, and it remains unknown whether LIPFENDRA lowers those risks.
What the LIPFENDRA FDA Approval Means for Patients
For patients managing persistently high LDL-C despite statin therapy, LIPFENDRA’s oral, once-daily dosing removes the injection requirement that has defined PCSK9 inhibition since monoclonal antibody versions first reached the market. Because elevated LDL-C is a well-established, modifiable risk factor for atherosclerotic cardiovascular disease, an oral option may help address adherence concerns for patients reluctant to self-inject. Prescribers should weigh LIPFENDRA against a patient’s full cardiovascular risk profile and refer to the full prescribing information for dosing, contraindications, and monitoring guidance.
About LIPFENDRA (Enlicitide) Tablets 20 mg
LIPFENDRA is an oral proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor, FDA-approved as an adjunct to diet and exercise to lower LDL-C in adults with hypercholesterolemia, including HeFH. As a macrocyclic peptide, it blocks PCSK9 from binding to LDL receptors, allowing more receptors to remain active on liver cells to clear LDL-C from circulation. Merck notes that cardiovascular outcomes trials of other PCSK9 inhibitors, used with statins or as monoclonal antibody add-on therapy, have shown that lowering LDL-C reduces major adverse cardiovascular events (MACE) risk, though LIPFENDRA’s own outcomes data are still pending from CORALreef Outcomes.
